地西他滨治疗骨髓增生异常综合征和急性髓系白血病的临床效果

Clinical effect of dicitabine in the treatment of myelodysplastic syndrome and acute myeloid leukemia

目的分析地西他滨治疗骨髓增生异常综合征和急性髓系白血病的临床效果。方法将在我院治疗骨髓增生异常综合征和急性髓系白血病的96例患者作为研究对象,其中骨髓增生异常24例,急性髓系白血病72例,根据治疗方法不同将患者分为对照组和试验组,各48例。对照组患者采用马法兰联合醋酸泼尼松治疗,试验组采用地西他滨治疗。比较两组的治疗效果。结果试验组的治疗总有效率为72.92%,显著高于对照组的18.75%,差异有统计学意义(P<0.05)。对照组骨髓抑制伴发热发生率为20.83%,试验组骨髓抑制伴发热发生率为62.50%,组间比较,差异有统计学意义(P<0.05)。结论使用地西他滨治疗骨髓增生异常综合征和急性髓系白血病有一定的效果,可以延缓病情的发展,可以在临床上推广使用。

Objective To analyze the clinical effect of dicitabine in the treatment of myelodysplastic syndrome and acute myeloid leukemia. Methods Ninety-six patients with myelodysplastic syndrome and acute myeloid leukemia treated in our hospital were selected as the research objects, including 24 cases of myelodysplastic disorder and 72 cases of acute myeloid leukemia. The patients were divided into control group and experimental group according to different treatment methods, with 48 cases in each group. The control group was treated with malphalan combined with prednisone acetate, and the experimental group was treated with dicetabine. The therapeutic effects of the two groups were compared. Results The total effective rate of treatment in the experimental group was 72.92%, which was significantly higher than 18.75% of the control group (P<0.05). The incidence of bone marrow depression with fever was 20.83% in the control group and 62.50% in the experimental group, there were significant differences between the two groups (P<0.05). Conclusion Dicetabine is effective in the treatment of myelodysplastic syndrome and acute myeloid leukemia. It can delay the development of the disease and can be widely used in clinic.